-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10

Benzinga·08/25/2026 14:01:04
Listen to the news
TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.